Tolazoline Hydrochloride

CHEMBL1689 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
196.7 g/mol
LogP
Phase
4

Tolazoline hydrochloride is the hydrochloride salt form of tolazoline, an alpha-adrenergic antagonist and vasodilator previously used for pulmonary hypertension in neonates. See tolazoline for complete pharmacological details. This salt form was used in intravenous preparations for treatment of persistent pulmonary hypertension.

Peso molecular

196,6700 g/mol

TPSA

24,40 Ų

Mecanismo de acción

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.c1ccc(CC2=NCCN2)cc1

InChI

InChI=1S/C10H12N2.ClH/c1-2-4-9(5-3-1)8-10-11-6-7-12-10;/h1-5H,6-8H2,(H,11,12);1H

Molecular Formula

C10H13ClN2

HBD / HBA

2 / 1

Enlaces Rotables

2

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Tolazoline hydrochloride is the hydrochloride salt form of tolazoline, an alpha-adrenergic antagonist and vasodilator previously used for pulmonary hypertension in neonates. See tolazoline for complete pharmacological details. This salt form was used in intravenous preparations for treatment of persistent pulmonary hypertension.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Tolazoline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1689. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6048. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.